We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

85 hedge funds and large institutions have $393M invested in Krystal Biotech in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

80% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 20

12% more funds holding

Funds holding: 76 → 85 (+9)

6.99% more ownership

Funds ownership: 58.01% → 65% (+7%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $397M → $393M (-$4.87M)

Holders
85
Holders Change
+9
Holders Change %
+11.84%
% of All Funds
1.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
14
Increased
36
Reduced
20
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$13.8M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$9.95M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$9.73M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$8.9M
5
BlackRock
BlackRock
New York
+$6.71M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$6.71M
2
Millennium Management
Millennium Management
New York
-$4.74M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.09M
4
O
OrbiMed
New York
-$1.79M
5
MIM
Monashee Investment Management
Massachusetts
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$39.9M – – –
RG
2
Redmile Group
California
$37.4M -$89.4K -2,000 -0.2%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$37.4M +$6.65M +148,679 +16%
BBA
4
Baker Bros. Advisors
New York
$35.9M – – –
FM
5
Frazier Management
Washington
$31.1M – – –
BlackRock
6
BlackRock
New York
$26.1M +$6.71M +150,115 +25%
O
7
OrbiMed
New York
$20.9M -$1.79M -40,056 -6%
Vanguard Group
8
Vanguard Group
Pennsylvania
$20.7M +$4.4M +98,465 +20%
Citadel Advisors
9
Citadel Advisors
Florida
$18.7M +$1.84M +41,056 +8%
State Street
10
State Street
Massachusetts
$16.2M +$13.8M +308,298 +195%
CCM
11
Consonance Capital Management
New York
$7.78M +$1.88M +42,000 +23%
PAMU
12
Pictet Asset Management (UK)
United Kingdom
$7.73M +$9.95M +222,657 New
Lord, Abbett & Co
13
Lord, Abbett & Co
New Jersey
$7.56M +$9.73M +217,750 New
VOYA Investment Management
14
VOYA Investment Management
Georgia
$6.92M +$8.9M +199,151 New
AG
15
Artal Group
Luxembourg
$5.21M -$6.71M -150,000 -50%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$4.98M +$1.06M +23,629 +20%
Northern Trust
17
Northern Trust
Illinois
$4.97M +$4.61M +103,065 +258%
Carson Wealth (CWM LLC)
18
Carson Wealth (CWM LLC)
Nebraska
$4.22M – – –
KCM
19
Knoll Capital Management
Florida
$4.17M -$1.2M -26,878 -18%
SFM
20
Sphera Funds Management
Israel
$4.08M – – –
NIP
21
Nicholas Investment Partners
California
$3.81M -$18K -402 -0.4%
EI
22
EAM Investors
California
$3.05M +$289K +6,467 +8%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$2.52M +$353K +7,890 +12%
Verition Fund Management
24
Verition Fund Management
Connecticut
$2.4M +$293K +6,544 +10%
CS
25
Credit Suisse
Switzerland
$2.35M -$70.4K -1,575 -2%
1
2 3 4

KRYS Hedge Fund Activity: Q3 2019 in Review

85 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2019, worth a combined $393M — down 1.2% from $397M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new KRYS positions and 5 closed out — a net gain of 9 holders — while 36 added to existing stakes and 20 trimmed.

The largest buyer was State Street, adding an estimated $13.8M. The largest seller was Artal Group, cutting an estimated $6.71M.

  • 85 institutional investors held Krystal Biotech (KRYS) as of Q3 2019, up from 76 in Q2 2019.
  • Funds reported $393M of Krystal Biotech stock for Q3 2019, down 1.2% quarter-over-quarter.
  • 14 funds opened new Krystal Biotech positions in Q3 2019 and 5 closed out, a net change of +9 holders.
  • The largest Krystal Biotech buyer in Q3 2019 was State Street, an estimated $13.8M added.
  • The largest Krystal Biotech seller in Q3 2019 was Artal Group, an estimated $6.71M sold.

Based on aggregated 13F filings for Q3 2019.